Two medical expert organizations recently issued an updated recommendation for all patients diagnosed with aggressive breast cancer to undergo tests for detection of a particular cancer-progressing protein.
The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) joined forces to emphasize the impact of the human epidermal growth factor receptor 2 or HER2 protein, and how its amplification in the body can lead to a heightened development of breast cancer. Dr. Antonio Wolff of Baltimore’s Johns Hopkins Kimmel Comprehensive Cancer Center and co-chair of the joint panel pressed on this matter. “HER2 is among the first targets in breast cancer that helped define a very specific subtype of breast cancer that affects about 30,000 to 40,000 patients each year just in the U.S.,” said Wolff in a news item.
HER2 is a protein present in the human body in the form of the ERBB2 gene, which, when found in the body at high levels, could result in tumors that grow faster and are more invasive.
Dr. Elizabeth Hammond, who co-chairs the panel with Dr. Wolff and works as pathology professor at Salt Lake City’s University of Utah School of Medicine, shared the importance of updating the guidelines for breast cancer testing and treatment. “We want to make sure that a woman living in a rural area has the same opportunity for testing as a woman living near a major medical center,” Hammond said.
Under the new guidelines, recommendations include the following: HER2 testing for women with invasive and metastatic breast cancer, focused treatment on HER2-positive cases, and prohibition of HER2-negative patients from taking HER2-focused medication.